Our mission is to improve cancer patients’ outcomes by ensuring each patient receives the right treatment the first time. ARTIDIS nanomechanical analysis platform is the first of its kind, pioneering an unprecedented method of diagnosing and optimizing treatment for cancer. Able to seamlessly integrate with the standard of care, our technology can be scaled to capture clinically relevant biological information across the patient’s journey, for a variety of diseases.
Decoding the physics of cancer
Unlocking a new dimension of powerful insights so each patient can receive the right treatment, the first time.
How to change the status quo…
We are the first transformative bedside cancer diagnosis and treatment optimization technology advancing cancer diagnostics and treatment optimization with mechanobiology.
Revolutionizing Cancer Care with ARTIDIS
Revolutionizing Cancer Care with ARTIDIS
Current cancer treatment response rates to first-line therapies remain low. ARTIDIS is transforming this reality by combining groundbreaking insights with a holistic data platform to personalize the patient journey and optimize therapy outcomes. Our technology provides rapid cancer diagnosis, evaluates tumor aggressiveness, and predicts the likelihood of metastasis using a proprietary nanomechanical biomarker. The ARTIDISNET platform integrates this biomarker with each patient’s clinical data to guide personalized therapy decisions. By delivering precise diagnoses and enabling effective treatment strategies, we empower patients and clinicians with the confidence to make the best choices for improved outcomes.Insufficient tools for cancer treatment optimization
For every one life saved during cancer treatment, there are 3 to 10 patients who are overtreated since there are no reliable biomarkers supporting the doctor’s decision-making. This creates unnecessary emotional burden and financial inflation. ARTIDIS evaluates cancer aggressiveness and enables the development of personalized cancer treatment plans based on the nanomechanical biomarker.
This is a title
Another major issue in the current clinical workflow is a lack of accurate optimization tools for patients diagnosed with cancerous lesions. These tools would prevent under- or overtreatment and improve patient outcomes. In the area of breast cancer, for example, we currently count 3-10 overtreated patients for every patient life saved (Marmot et al., 2012).This has a massive impact on the patient’s quality of life due to the severe side effects accompanying the cancer treatment. In addition, there is a high cost burden for the entire health ecosystem.
